Relevance of Circulating Tumor Cells as Predictive Markers for Cancer Incidence and Relapse.
Chaithanya ChelakkotHobin YangYoung-Kee ShinPublished in: Pharmaceuticals (Basel, Switzerland) (2022)
Shedding of cancer cells from the primary site or undetectable bone marrow region into the circulatory system, resulting in clinically overt metastasis or dissemination, is the hallmark of unfavorable invasive cancers. The shed cells remain in circulation until they extravasate to form a secondary metastatic lesion or undergo anoikis. The circulating tumor cells (CTCs) found as single cells or clusters carry a plethora of information, are acknowledged as potential biomarkers for predicting cancer prognosis and cancer progression, and are supposed to play key roles in determining tailored therapies for advanced diseases. With the advent of novel technologies that allow the precise isolation of CTCs, more and more clinical trials are focusing on the prognostic and predictive potential of CTCs. In this review, we summarize the role of CTCs as a predictive marker for cancer incidence, relapse, and response to therapy.
Keyphrases
- circulating tumor cells
- papillary thyroid
- clinical trial
- squamous cell
- circulating tumor
- induced apoptosis
- bone marrow
- squamous cell carcinoma
- lymph node metastasis
- risk factors
- stem cells
- randomized controlled trial
- small cell lung cancer
- mesenchymal stem cells
- oxidative stress
- cell cycle arrest
- young adults
- signaling pathway
- extracorporeal membrane oxygenation
- open label
- endoplasmic reticulum stress
- climate change
- cell therapy
- phase ii
- phase iii